DWTX8:45 AMDogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b TrialEnrollment • Phase 2Enrollment milestone Mon, Sep 14, 2026, 8:45 AM EDTGvirios.com
DWTX8:30 AMDogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026Results Call • Phase 2Results call Tue, Sep 1, 2026, 10:00 AM ETGvirios.com
DWTX8:30 AMDogwood Therapeutics Announces Second Quarter 2026 Financial ResultsEnrollment • Phase 2Enrollment milestone Thu, Aug 13, 2026, 8:30 AM EDTGvirios.com
DWTX8:30 AMDogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026Enrollment • Phase 2Enrollment milestone Mon, Jul 20, 2026, 8:30 AM EDTGvirios.com
DWTX8:45 AMDogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Boardvirios.com